Skip to content

Effectiveness of Tobacco Cessation Interventions in Sweden

Effectiveness of Tobacco Cessation Interventions for Different Groups of Users in Sweden: a National Prospective Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04819152
Acronym
RSP
Enrollment
8000
Registered
2021-03-26
Start date
2020-04-09
Completion date
2023-12-31
Last updated
2022-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cigarette Use, Electronic, Smoking, Tobacco Use

Keywords

National cohort study, Effectiveness, Tobacco use cessation, Smoking cessation, Vulnerable groups

Brief summary

Smoking is still one of the most important risk factors causing morbidity and mortality in Sweden. Every year, 12,000 Swedish citizens die prematurely from smoking, and smoking is responsible for up to 60% of the inequity in health. Though the smoking prevalence is relatively low in Sweden in an international context (8% and 10% for men and women respectively in 2016), specific vulnarable groups have a very high prevalence; e.g. about 80% in alcohol and drug abusers. Furthermore, Sweden has a unique high prevalence of snus users and in 2016 the daily use of tobacco was 25% for men and 14% for women. In addition, products such as cigarettes, snus, and e-cigettes are often mixed. Despite the fact that about a thousand counsellors have been trained in manual-based person-centred tobacco cessation interventions in Sweden, the effectiveness of the interventions remains unknown, as a follow-up on effect of in-person interventions is not systematically collected in Sweden. Therefore, as of today it is not possible, on a national level, to compare the effectiveness of differences in these interventions, providers, or different groups of tobacco users including disadvantaged and vulnerable groups. In this study the investigators will evaluate the effectiveness of already implemented in-person cessation interventions targeting smoking, use of snus and/or e-cigarettes, focusing on disadvantaged and vulnerable groups of tobacco users. Furthermore, important factors associated with a successful outcome after controlling for confounders will be identified (in relation to programme, patients and setting).

Interventions

Already implemented in-person (including online meetings) tobacco cessation interventions in Sweden

Sponsors

Lund University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* All adult tobacco users (of at least 18 years of age), including disadvantaged and vulnerable patients, receiving an in-person intervention (incl. online meetings) for tobacco cessation (smoking, snus and/or e-cigarettes) are eligible for inclusion in the project after giving informed consent. * Both individual and group-based interventions can be included.

Exclusion criteria

* Withdrawing consent. * Reduced ability to give informed consent, due to inadequate language skills, dementia, and other conditions.

Design outcomes

Primary

MeasureTime frameDescription
% of patients that are continuously smokefree6 monthsSelf-reported smoking status, questionnaire completed by telephone interview

Secondary

MeasureTime frameDescription
% of patients that are smokefreeOn completion of the tobacco cessation programme (app. 1 month after quitting)Counsellor observed smoking status, questionnaire completed by counsellor
% of patients that have been smokefree for at least the latest 14 days6 monthsSelf-reported smoking status, questionnaire completed by telephone interview
% of patients that are satisfied with the smoking cessation intervention6 monthsSelf-reported patient-satisfaction, questionnaire completed by telephone interview

Countries

Sweden

Contacts

Primary ContactMette Rasmussen, PhD
mette.rasmussen@med.lu.se+4538163850
Backup ContactHanne Tønnesen, DSc
hanne.tonnesen@med.lu.se+46724531481

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026